From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...
China's national regulator has granted a rapid approval for Roche’s lung cancer treatment Alecensa just months after European and American approvals, following a revamp of the country's notoriously ...
Lorviqua will be available for ALK-positive NSCLC patients whose disease has progressed after treatment with Roche’s Alecensa (alectinib) or Novartis’ Zykadia (ceritinib). NICE had a rethink after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback